메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Hepatic steatosis is common in obese individuals with hyperinsulinemia and is an important hepatic manifestation of metabolicsyndrome. Sterol regulatory binding protein-1c (SREBP-1c) is a master regulator of lipogenic gene expression in the liver. Hyperinsulinemia induces transcription of SREBP-1c via activation of liver X receptor (LXR) and specificity protein 1 (Sp1). Cilostazol is an antiplatelet agent that prevents atherosclerosis and decreases serum triglyceride levels. However, little is knownabout the effects of cilostazol on hepatic lipogenesis. Here, we examined the role of cilostazol in the regulation of SREBP-1ctranscription in the liver. The effects of cilostazol on the expression of SREBP-1c and its target genes in response to insulin oran LXR agonist (T0901317) were examined using real-time RT-PCR and western blot analysis on cultured hepatocytes. Toinvestigate the effect of cilostazol on SREBP-1c at the transcriptional level, transient transfection reporter assays andelectrophoretic mobility shift assays (EMSAs) were performed. Cilostazol inhibited insulin-induced and LXR-agonist-inducedexpression of SREBP-1c and its downstream targets, acetyl-CoA carboxylase and fatty acid synthase, in cultured hepatocytes. Cilostazol also inhibited activation of the SREBP-1c promoter by insulin, T0901317 and Sp1 in a luciferase reporter assay. EMSA analysis showed that cilostazol inhibits SREBP-1c expression by repressing the binding of LXR and Sp1 to the promoterregion. These results indicate that cilostazol inhibits insulin-induced hepatic SREBP-1c expression via the inhibition of LXRand Sp1 activity and that cilostazol is a negative regulator of hepatic lipogenesis.

목차

등록된 정보가 없습니다.

참고문헌 (20)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0